Search Page

1

Cite

Share

Effects of pulsed-radiofrequency neuromodulation on the rat with overactive bladder.

Jen E, Hsieh TH, Lu TC, Chen MC, Lee FJ, Lin CT, Chen SC, Chu PY, Peng CW, Lin CW. Jen E, et al. Neurourol Urodyn. 2017 Sep;36(7):1734-1741. doi: 10.1002/nau.23183. Epub 2016 Nov 28. Neurourol Urodyn. 2017. PMID: 27891636

Cite

Share

2

Cite

Share

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R. Jen EY, et al. Clin Cancer Res. 2020 Feb 1;26(3):532-536. doi: 10.1158/1078-0432.CCR-19-2329. Epub 2019 Sep 23. Clin Cancer Res. 2020. PMID: 31548341

Cite

Share

3

Cite

Share

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.

Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, Norsworthy KJ, Przepiorka D, Nie L, Liu J, Sheth CM, Shapiro M, Farrell AT, Pazdur R. Jen EY, et al. Clin Cancer Res. 2018 Jul 15;24(14):3242-3246. doi: 10.1158/1078-0432.CCR-17-3179. Epub 2018 Feb 23. Clin Cancer Res. 2018. PMID: 29476018

Cite

Share

4

Cite

Share

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.

Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, Sridhara R, Deisseroth A, Philip R, Farrell AT, Pazdur R. Jen EY, et al. Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25. Clin Cancer Res. 2019. PMID: 30254079

Cite

Share

5

Cite

Share

IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA. Jen EY, et al. Melanoma Res. 2012 Feb;22(1):19-29. doi: 10.1097/CMR.0b013e32834d2506. Melanoma Res. 2012. PMID: 22027907 Free PMC article.

Cite

Share

6

Cite

Share

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.

Jen EY, Wang X, Li M, Li H, Lee SL, Ni N, Przepiorka D, Vallejo J, Leong R, Ma L, Gehrke BJ, McLamore S, Theoret MR, de Claro RA. Jen EY, et al. Clin Cancer Res. 2022 Jul 15;28(14):2989-2993. doi: 10.1158/1078-0432.CCR-21-4525. Clin Cancer Res. 2022. PMID: 35325108 Clinical Trial.

Cite

Share

7

Cite

Share

Clinical characteristics and treatment experience of individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE): Findings from an online caregiver survey.

Cutts A, Savoie H, Hammer MF, Schreiber J, Grayson C, Luzon C, Butterfield N, Pimstone SN, Aycardi E, Harden C, Yonan C, Jen E, Nguyen T, Carmack T, Haubenberger D. Cutts A, et al. Among authors: jen e. Seizure. 2022 Apr;97:50-57. doi: 10.1016/j.seizure.2022.03.008. Epub 2022 Mar 10. Seizure. 2022. PMID: 35325842 Free article.

Cite

Share

8

Cite

Share

IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.

Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA. Poindexter NJ, et al. Among authors: jen e. Exp Dermatol. 2010 Aug;19(8):714-22. doi: 10.1111/j.1600-0625.2010.01077.x. Exp Dermatol. 2010. PMID: 20545760 Free PMC article.

Cite

Share

9

Cite

Share

Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes.

Bigelow RL, Jen EY, Delehedde M, Chari NS, McDonnell TJ. Bigelow RL, et al. Among authors: jen ey. J Invest Dermatol. 2005 Feb;124(2):457-65. doi: 10.1111/j.0022-202X.2004.23590.x. J Invest Dermatol. 2005. PMID: 15675968 Free article.

Cite

Share

10

Cite

Share

Design an international blended professional development model for gifted education: An evaluation study.

Jen E, Hoogeveen L. Jen E, et al. Eval Program Plann. 2022 Apr;91:102034. doi: 10.1016/j.evalprogplan.2021.102034. Epub 2021 Oct 30. Eval Program Plann. 2022. PMID: 34753615 Free article.

Cite

Share